Lupin Eyes 20% Growth Rate In U.S. From 110 Applications To FDA
This article was originally published in PharmAsia News
Executive Summary
Lupin is aiming for a 20% growth rate in the U.S. market, relying on approvals of many of the 110 drugs it has filed for approval by the FDA within the next four years, according to S Ramesh, President and CFO.
You may also be interested in...
FDA To Ramp Up ASCA Pilot In 2021
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
Scotland's MGB Plots Phase III For Promising Antibacterial
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AstraZeneca Vaccine May Only Gain EU Approval In Under 70s
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
Need a specific report? 1000+ reports available
Buy Reports